I-Ruxolitinib inokusebenza okuthembisayo kwizifo ze-myeloproliferative

Ruxolitinib, eyaziwa ngokuba yi-ruxolitinib e-China, yenye "yeziyobisi ezitsha" ezichazwe ngokubanzi kwizikhokelo zekliniki zonyango lwezifo ze-hematological kwiminyaka yamuva nje, kwaye ibonise ukusebenza okuthembisayo kwizifo ze-myeloproliferative.
Ichiza elijoliswe kuyo i-Jakavi ruxolitinib inokuthintela ngokufanelekileyo ukusebenza kwetshaneli yonke ye-JAK-STAT kunye nokunciphisa isignali ephuculweyo ngokungaqhelekanga yetshaneli, ngaloo ndlela ifezekisa ukusebenza kakuhle.Isenokusetyenziswa kunyango lwezifo ezahlukeneyo, nakwindawo engaqhelekanga ye-JAK1.
Ruxolitinibi-kinase inhibitor eboniswe kunyango lwezigulane ezine-myelofibrosis ephakathi okanye ephezulu, kuquka i-myelofibrosis ephambili, i-post-geniculocytosis myelofibrosis, kunye ne-post-primary thrombocythemia myelofibrosis.
Uphononongo olufanayo lweklinikhi (n = 219) izigulane ezingapheliyo kunye ne-intermediate-risk-2 okanye i-MF, izigulane ezine-MF emva kwe-erythroblastosis yokwenene, okanye izigulane ezine-MF emva kwe-thrombocytosis yokuqala ukuya kumaqela amabini, enye ifumana i-ruxolitinib yomlomo 15 ukuya kwi-20 mgbid. (n=146) kwaye omnye ufumana iyeza lokulawula elilungileyo (n=73).Iziphelo eziphambili kunye nezona ziphambili zesibini zophando ziyipesenti yezigulane ezine-≥35% yokunciphisa umthamo we-spleen (ihlolwe ngumfanekiso we-magnetic resonance imaging okanye i-computed tomography) kwiiveki ze-48 kunye ne-24, ngokulandelanayo.Iziphumo zibonise ukuba ipesenti yezigulane ezingaphezu kwe-35% yokunciphisa umthamo we-spleen ukusuka kwisiseko kwiveki ye-24 yi-31.9% kwiqela lonyango xa kuthelekiswa ne-0% kwiqela lokulawula (P <0.0001);kunye nepesenti yezigulane ezingaphezu kwe-35% yokunciphisa umthamo we-spleen ukusuka kwisiseko kwiveki ye-48 yayingu-28.5% kwiqela lonyango xa kuthelekiswa ne-0% kwiqela lokulawula (P <0.0001).Ukongeza, i-ruxolitinib iphinde yanciphisa iimpawu ezipheleleyo kunye nokuphucula kakhulu umgangatho wobomi kwizigulane.Ngokusekwe kwiziphumo zolulingo lwezonyango zibini,ruxolitinibyaba lichiza lokuqala elavunywa yi-US FDA kunyango lwezigulane ezine-MF.


Ixesha lokuposa: Mar-02-2022